We are live on ! Find out more
BIOTW

Biotech Acquisition Company Warrant
BIOTW

Delisted

BIOTW was delisted on the 2nd of February, 2023.

39 hedge funds and large institutions have $6.51M invested in Biotech Acquisition Company Warrant in 2021 Q3 according to their latest regulatory filings, with 6 funds opening new positions, 5 increasing their positions, 3 reducing their positions, and 1 closing their positions.

New
Increased
Maintained
Reduced
Closed

500% more first-time investments, than exits

New positions opened: 6 | Existing positions closed: 1

67% more repeat investments, than reductions

Existing positions increased: 5 | Existing positions reduced: 3

15% more funds holding

Funds holding: 3439 (+5)

3% more capital invested

Capital invested by funds: $6.34M → $6.51M (+$166K)

Holders
39
Holders Change
+5
Holders Change %
+14.71%
% of All Funds
0.68%
Holding in Top 10
Holding in Top 10 Change
Holding in Top 10 Change %
% of All Funds
New
6
Increased
5
Reduced
3
Closed
1
Calls
$1.36M
Puts
Net Calls
+$1.36M
Net Calls Change
+$214K
Name Holding Trade Value Shares
Change
Change in
Stake
RCM
1
Radcliffe Capital Management
Pennsylvania
$1.98M
LP
2
LMR Partners
United Kingdom
$487K
Citadel Advisors
3
Citadel Advisors
Florida
$444K +$36 +49 +0%
RA
4
Ramius Advisors
New York
$412K +$90.8K +122,047 +24%
CCP
5
Corbin Capital Partners
New York
$306K
LA
6
Linden Advisors
New York
$220K
KCM
7
Kingstown Capital Management
New York
$198K
MI
8
MMCAP International
Cayman Islands
$198K
SRCM
9
Sage Rock Capital Management
New York
$189K +$213K +286,900 New
ACM
10
Atalaya Capital Management
New York
$184K
Blackstone Inc
11
Blackstone Inc
New York
$165K
PC
12
Periscope Capital
Ontario, Canada
$164K
DCM
13
DG Capital Management
New York
$148K
PAMP
14
Polar Asset Management Partners
Ontario, Canada
$139K
BFM
15
Boothbay Fund Management
New York
$134K
Nomura Holdings
16
Nomura Holdings
Japan
$127K
FTCM
17
Fir Tree Capital Management
New York
$99K
SC
18
Sculptor Capital
New York
$97K
DKCM
19
Davidson Kempner Capital Management
New York
$96K
TCM
20
Tenor Capital Management
New York
$93K
RCM
21
Rivernorth Capital Management
Florida
$74K +$83.7K +112,499 New
CH
22
CVI Holdings
Delaware
$66K
PSAMP
23
P. Schoenfeld Asset Management (PSAM)
New York
$66K
TI
24
Telemetry Investments
New York
$66K +$11.2K +15,025 +18%
ACA
25
Arena Capital Advisors
California
$66K +$74.4K +100,000 New

BIOTW Hedge Fund Activity: Q3 2021 in Review

39 of the 5,712 institutional investors tracked by Wall St. Rank reported a position in Biotech Acquisition Company Warrant (BIOTW) for Q3 2021, worth a combined $6.51M — up 2.6% from $6.34M a quarter earlier.

Buyers outnumbered sellers: 6 funds opened new BIOTW positions and 1 closed out — a net gain of 5 holders — while 5 added to existing stakes and 3 trimmed.

The largest buyer was Sage Rock Capital Management, opening a new position worth an estimated $213K. The largest seller was Kamunting Street Capital Management, exiting entirely with an estimated $137K sold.

  • 39 institutional investors held Biotech Acquisition Company Warrant (BIOTW) as of Q3 2021, up from 34 in Q2 2021.
  • Funds reported $6.51M of Biotech Acquisition Company Warrant stock for Q3 2021, up 2.6% quarter-over-quarter.
  • 6 funds opened new Biotech Acquisition Company Warrant positions in Q3 2021 and 1 closed out, a net change of +5 holders.
  • The largest Biotech Acquisition Company Warrant buyer in Q3 2021 was Sage Rock Capital Management, an estimated $213K added.
  • The largest Biotech Acquisition Company Warrant seller in Q3 2021 was Kamunting Street Capital Management, an estimated $137K sold.

Based on aggregated 13F filings for Q3 2021.